Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

Biotech exit markets are reopening, with JPMorgan bankers saying the IPO window is back for high-quality names even as many companies are being bought before listing. JPMorgan cited 6 biopharma deals in the $5 billion-$15 billion range so far in 2026, versus 7 such deals in all of 2025, suggesting larger strategic transactions are accelerating. The tone is constructive for healthcare M&A and IPO activity, though capital remains highly selective and concentrated in best-in-class assets.

Analysis

The key read-through is not “IPO window reopening” but a tightening of the exit hierarchy: the best assets are increasingly more valuable as strategic targets than as public listings. That should compress the dispersion between truly differentiated platforms and everyone else, because capital is now rewarding proof of product moat, not story quality. In practice, that means late-stage biotech valuations may bifurcate further over the next 6-12 months, with first-in-class / category-leading assets seeing higher takeout probability and mediocre platforms getting stranded.

For Big Pharma, this is a pipeline insurance trade against the patent cliff, and the willingness to pay up signals that internal R&D remains insufficient for near-term growth targets. The second-order effect is that royalty financing and structured pre-commercial capital should expand as a bridge for companies that are good enough to command optionality but not yet strong enough to price an IPO cleanly. That can support the broader private biotech ecosystem, but it also raises the bar for public-market comps because the best names may be removed before they ever list.

The main risk to the bullish M&A setup is not macro; it is competitive de-rating. If public biotech sentiment improves faster than M&A appetite, boards may choose IPOs instead of strategic sales, which would dilute scarcity value and mute takeover premiums. Another reversal trigger is if regulators or shareholders push back on large upfront checks after a few headline deals, but that looks more like a months-to-years risk than a near-term one.

The most actionable implication is to own the acquirers with credible balance sheets and strategic urgency, while selectively expressing long optionality on pre-IPO winners that are plausibly takeout candidates. Nuvalent is the cleanest proof point that oncology assets can command large premiums, and similar assets with differentiated mechanisms should remain the focal point for deal flow. JPMorgan benefits indirectly from higher fee pools and more financing complexity, but the bigger equity alpha sits in the companies likely to be acquired or the firms that can finance them.

Key Decisions for Investors

• Long GSK over NVS for the next 3-6 months: GSK has more visible willingness to pay up for strategic oncology assets, so it should capture the near-term M&A narrative. Risk/reward: better rerating if deal activity stays hot; main risk is integration or a pause in large-check appetite.
• Initiate a tactical long in NUVL on any post-deal volatility or hold through closing if timing remains within 1-2 quarters: the asset becomes a read-through for similar oncology platforms, and takeover premium compression should be limited unless antitrust or financing conditions worsen.
• Pair trade: long a basket of differentiated late-stage private-biotech proxies / listed pre-revenue oncology names, short a basket of undifferentiated platform biotech names over 3-6 months. The thesis is widening dispersion as capital concentrates into first-in-class assets; loser names likely face valuation resets if they lose dual-track optionality.
• Buy JPM on a 6-12 month horizon as a lower-beta beneficiary of reopening equity capital markets and rising healthcare M&A fees. Risk/reward is modest but cleaner than the biotech beta trade; upside comes from advisory and ECM monetization rather than directional deal exposure.
• Avoid chasing broad biotech ETFs until dispersion normalizes; instead, use downside-capped structures on sector leaders if you want exposure. A call spread or collar over 3-6 months is preferable to outright beta because the market is likely to reward only the top decile of assets.